Global Duchenne Muscular Dystrophy Drugs Market Forecast to Reach $6 Billion by 2030 at 13.4% CAGR
The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Forecasted Market Value Of The Analgesics Market Across 2026–2030?
The duchenne muscular dystrophy drugs market size has expanded quickly in recent years. It is forecasted to increase from $3.2 billion in 2025 to $3.64 billion in 2026, maintaining a compound annual growth rate (CAGR) of 13.5%. The market’s historical growth resulted from factors such as limited treatment options, increasing awareness of DMD, a growing pediatric patient population, the adoption of corticosteroids, and early-stage R&D in gene therapy.
The duchenne muscular dystrophy drugs market is anticipated to experience significant expansion over the coming years. This market is projected to reach $6.01 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.4%. This projected growth is driven by factors such as progress in exon skipping medications, breakthroughs in gene editing techniques, increased governmental and regulatory backing, growing capital allocation towards rare disease treatments, and the enlargement of specialized care and hospital infrastructures. Key trends anticipated during this period encompass a wider acceptance of exon skipping treatments, an increase in gene therapy strategies for DMD, a preference shift towards injectable and precisely targeted drug delivery methods, the broadening of online and hospital pharmacy distribution routes, and the creation of complementary therapies like myostatin inhibitors and utrophin modulators.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24213&type=smp
Which Market Drivers Are Supporting The Expansion Of The Analgesics Market?
The Duchenne muscular dystrophy (DMD) drugs market is anticipated to expand due to the increasing adoption of personalized medicine. This medical approach customizes treatments for individual patients, considering their genetic makeup, environmental influences, and lifestyle choices to enhance results and patient care. The rising demand for personalized medicine stems from progress in genomic technologies, allowing for accurate detection of genetic variations and the creation of bespoke treatments. For Duchenne muscular dystrophy (DMD) drugs, personalized medicine provides targeted therapies customized to each patient’s genetic profile, thereby boosting treatment efficacy. This approach also improves drug development by concentrating on particular genetic mutations, which leads to better treatment outcomes and comprehensive patient care. A notable example is cited by the Personalized Medicine Coalition (PMC), a US-based nonprofit, which reported in February 2024 that the U.S. Food and Drug Administration (FDA) sanctioned 26 new personalized medicines in 2023, marking a considerable rise from the 12 approved in 2022. Consequently, the expansion of personalized medicine is a key driver for the Duchenne muscular dystrophy (DMD) drugs market.
What Segmentation Levels Are Considered In The Analgesics Market?
The duchenne muscular dystrophy drugs market covered in this report is segmented –
1) By Drug Type: Exon Skipping Drugs, Corticosteroids, Gene Therapy, Other Drug Types
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Exon Skipping Drugs: Eteplirsen, Golodirsen, Viltolarsen, Casimersen, Other Exon Skipping Therapies
2) By Corticosteroids: Prednisone, Deflazacort, Other Corticosteroids
3) By Gene Therapy: Micro-dystrophin Gene Therapy, CRISPR/Cas9-Based Gene Editing, Stem Cell-Based Gene Therapy, Other Gene Therapies
4) By Other Drug Types: Utrophin Modulators, Anti-Inflammatory Agents, Antisense Oligonucleotides, Myostatin Inhibitors, Other Supportive Therapies
What Trends Are Projected To Affect The Duchenne Muscular Dystrophy Drugs Market?
Leading companies in the Duchenne muscular dystrophy (DMD) drugs market are prioritizing the creation of innovative therapies, such as corticosteroids, with the goal of improving muscle strength, slowing disease progression, and enhancing overall patient outcomes. Corticosteroids are a type of steroid hormone, either naturally produced in the adrenal glands or synthetically developed as medicines, designed to diminish inflammation and suppress the immune system. For example, in March 2024, Catalyst Pharmaceuticals, a US-based biopharmaceutical firm, unveiled AGAMREE (vamorolone) oral suspension 40 mg/mL, a Food and Drug Administration (FDA)-approved medication for Duchenne muscular dystrophy in patients aged two and older. AGAMREE functions as a corticosteroid by reducing inflammation and stabilizing muscle cell membranes, which helps to decelerate the disease’s advancement.
Which Leading Firms Are Contributing To The Growth Of The Analgesics Market?
Major companies operating in the duchenne muscular dystrophy drugs market are Pfizer Inc, Sanofi S.A, Novartis AG, Italfarmaco S.p.A, Sarepta Therapeutics Inc, PTC Therapeutics Inc, FibroGen Inc, Wave Life Sciences Ltd, Solid Biosciences Inc, NS Pharma, Capricor Therapeutics Inc, Santhera Pharmaceuticals, ReveraGen BioPharma, Antisense Therapeutics Limited, Catalyst Pharmaceuticals Inc, EspeRare Foundation, Cure Rare Disease, Akashi Therapeutics Inc, BioMarin Pharmaceutical Inc, Daiichi Sankyo Co Ltd, Nippon Shinyaku Co Ltd, Regenxbio Inc, Ultragenyx Pharmaceutical Inc, Dyne Therapeutics Inc, Entrada Therapeutics Inc.
Read the full duchenne muscular dystrophy drugs market report here:
How Is The Analgesics Market Distributed Across Key Geographic Regions?
North America was the largest region in the duchenne muscular dystrophy (DMD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the duchenne muscular dystrophy drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Analgesics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24213&type=smp
Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy Drugs Market 2026, By The Business Research Company
Duchenne Muscular Dystrophy Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report
Musculoskeletal Disorder Drugs Global Market Report 2026
Musculoskeletal Disorder Drugs Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
